NEUROONE MEDICAL TECHNOLOGIES Corp

Rule 10b5-1 Trading Plans - Directors and Section 16 Officers

During the three months ended March 31, 2025, none of the Company’s directors or Section 16 officers adopted orterminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any “non-Rule 10b5-1 trading arrangement”.

Inducement Plan Amendment

On May 20, 2025, the Company's board of directors adopted the Second Amendment (the***“Second Amendment”***) to the Company’s Inducement Plan, increasing the aggregate number of shares of common stock that may be issued pursuant to equity incentive awards under the Inducement Plan by 575,000 shares of common stock that may be issued pursuant to equity incentive awards under the Inducement Plan. The Company believes that the increase in the shares reserved under the Inducement Plan is necessary to allow it to attract qualified employees.

The foregoing description of the terms of the Second Amendment is qualified in its entirety by reference to the actual terms of the Second Amendment, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.